Browsing Tag
Obesity
1 post
Pfizer Inc. halts Phase 3 trial for oral GLP-1 candidate in obesity and type 2 diabetes patients
Pfizer Inc.’s stock PFE fell 4% premarket on Friday, following the company’s announcement that it will not proceed…